id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2017-P-2659-0005,FDA,FDA-2017-P-2659,Final Response Letter from FDA to Jubilant Generics Limited,Other,Reply,2017-12-12T05:00:00Z,2017,12,2017-12-12T05:00:00Z,,2017-12-12T17:23:20Z,,0,0,0900006482cfec92
FDA-2017-P-2659-0006,FDA,FDA-2017-P-2659,"Determination That NOROXIN (Norfloxacin) Tablets, 400 Milligrams,
Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness",Notice,Determinations,2017-12-12T05:00:00Z,2017,12,2017-12-12T05:00:00Z,,2017-12-12T18:27:25Z,2017-26693,0,0,0900006482cfd5ec
FDA-2017-P-2659-0004,FDA,FDA-2017-P-2659,Interim Response from FDA to Jubilant Generics,Other,Letter(s),2017-10-13T04:00:00Z,2017,10,2017-10-13T04:00:00Z,,2017-10-13T17:47:02Z,,0,0,0900006482bc8171
FDA-2017-P-2659-0003,FDA,FDA-2017-P-2659,"Attachment 1 Orange Book: Approved Drug Products with Therapeutic
Equivalence Evaluations re",Supporting & Related Material,Background Material,2017-04-28T04:00:00Z,2017,4,,,2017-04-28T11:44:34Z,,0,0,09000064825801e6
FDA-2017-P-2659-0001,FDA,FDA-2017-P-2659,Citizen Petition from Jubilant Generics,Other,Citizen Petition,2017-04-28T04:00:00Z,2017,4,2017-04-28T04:00:00Z,2017-10-25T03:59:59Z,2017-04-29T20:53:43Z,,0,0,09000064825801e0
FDA-2017-P-2659-0002,FDA,FDA-2017-P-2659,Acknowledgment Letter from FDA DDM to Jubilant Generics,Other,Acknowledgement Letter/Receipt,2017-04-28T04:00:00Z,2017,4,2017-04-28T04:00:00Z,,2017-04-28T11:44:26Z,,0,0,09000064825801e2